Moderna MRNA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.23B+14.5% | $1.94B-12.9% | $2.23B-27.5% | $3.08B-3.1% | $3.18B-1.8% | ||
| $1.73B+99.7% | $868M-24.8% | $1.16B-21.0% | $1.46B+0.3% | $1.46B-0.4% | ||
| $492M-54.3% | $1.08B-0.1% | $1.08B-33.4% | $1.62B-6.0% | $1.72B-3.0% | ||
| 22.1%-33.2pp | 55.3%+7.1pp | 48.3%-4.2pp | 52.5%-1.6pp | 54.1%-0.7pp | ||
| $2.93B-6.6% | $3.13B-10.0% | $3.48B-8.8% | $3.82B-12.0% | $4.34B-4.6% | ||
| $979M-3.8% | $1.02B-4.1% | $1.06B-1.2% | $1.07B-3.4% | $1.11B-5.3% | ||
| $5.64B+12.3% | $5.02B-11.9% | $5.7B-10.3% | $6.35B-8.0% | $6.91B-3.8% | ||
| -$3.41B-11.0% | -$3.07B+11.2% | -$3.46B-5.8% | -$3.27B+12.2% | -$3.73B+5.5% | ||
| -153.3%+4.8pp | -158.1%-3.0pp | -155.2%-48.8pp | -106.3%+11.0pp | -117.4%+4.5pp | ||
| $296M-5.7% | $314M-6.3% | $335M-8.2% | $365M-7.6% | $395M-7.1% | ||
| -$22M-175% | -$8M+68.0% | -$25M+32.4% | -$37M+48.6% | -$72M+17.2% | ||
| -$3.14B-13.4% | -$2.77B+12.2% | -$3.15B-7.1% | -$2.95B+13.5% | -$3.41B+5.6% | ||
| $56M+3.7% | $54M+246% | -$37M+11.9% | -$42M+14.3% | -$49M-6.5% | ||
| -$3.19B-13.2% | -$2.82B+9.4% | -$3.12B-7.3% | -$2.9B+13.5% | -$3.36B+5.7% | ||
| -143.6%+1.6pp | -145.2%-5.6pp | -139.6%-45.3pp | -94.3%+11.4pp | -105.7%+4.4pp | ||
| -$8.15-12.1% | -$7.27+9.9% | -$8.07-7.2% | -$7.53+13.7% | -$8.73+5.9% | ||
| -$8.15-12.1% | -$7.27+9.9% | -$8.07-7.2% | -$7.53+13.7% | -$8.73+5.9% | ||
| 1.6B+0.6% | 1.6B+0.3% | 1.5B-0.6% | 1.6B+0.3% | 1.6B+0.3% | ||
| 1.6B+0.6% | 1.6B+0.3% | 1.5B+0.3% | 1.5B+0.3% | 1.5B+0.3% | ||
| -$22M-175% | -$8M+68.0% | -$25M+32.4% | -$37M+48.6% | -$72M+17.2% | ||
| $2.23B+14.5% | $1.94B-12.9% | $2.23B-27.5% | $3.08B-3.1% | $3.18B-1.8% | ||
| -$3.18B-11.1% | -$2.86B+12.2% | -$3.26B-6.2% | -$3.07B+13.3% | -$3.54B+5.8% | ||
| -142.8%+4.3pp | -147.1%-1.2pp | -145.8%-46.3pp | -99.6%+11.8pp | -111.3%+4.7pp | ||
| -$3.41B-11.0% | -$3.07B+11.2% | -$3.46B-5.8% | -$3.27B+12.2% | -$3.73B+5.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Moderna's revenue?
- Moderna (MRNA) generated $2.2B in revenue over the trailing twelve months, down 30.0% year over year.
- Is Moderna profitable?
- Moderna is not currently profitable: it reported a net loss of $3.2B over the trailing twelve months, a -143.6% net margin.
- What are Moderna's profit margins?
- Gross margin is 22.1% and operating margin is -153.3%, with a -143.6% net margin.
- What is Moderna's earnings per share?
- Moderna's diluted EPS over the trailing twelve months is $-8.15.
- Where does Moderna's income statement data come from?
- Every line is extracted from Moderna's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
